Antifungal Nail Lacquer for Enhanced Transungual Delivery of Econazole Nitrate
Abstract
1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Preparation of the Antifungal Nail Lacquer
2.3. Selection and Optimization of Excipients
2.4. Characterization of the Antifungal Nail Lacquers
2.4.1. Drying Time Test
2.4.2. Water Resistance Test
2.4.3. Adhesion Test
2.4.4. Viscosity
2.5. Handwashing Simulation Study
2.6. In Vitro Drug Release Testing
2.7. Ex Vivo Nail Permeation Study
2.8. Analytical Method for Drug Determination
2.9. Statistical Analysis
3. Results and Discussions
3.1. QTPP and Excipient Selection
3.2. Characterization of the Antifungal Nail Lacquers
3.3. In Vitro Drug Release Testing
3.4. Ex Vivo Nail Permeation Testing
5. Conclusions
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- To, M.J.; Brothers, T.D.; Van Zoost, C. Foot Conditions among Homeless Persons: A Systematic Review. PLoS ONE 2016, 11, e0167463. [Google Scholar] [CrossRef] [Scilit]
- Drake, L.A.; Scher, R.K.; Smith, E.B.; Faich, G.A.; Smith, S.L.; Hong, J.J.; Stiller, M.J. Effect of onychomycosis on quality of life. J. Am. Acad. Dermatol. 1998, 38, 702–704. [Google Scholar] [CrossRef] [Scilit]
- Szepietowski, J.C.; Reich, A.; Garlowska, E.; Kulig, M.; Baran, E.; Group, f.t.O.E.S. Factors Influencing Coexistence of Toenail Onychomycosis With Tinea Pedis and Other Dermatomycoses: A Survey of 2761 Patients. Arch. Dermatol. 2006, 142, 1279–1284. [Google Scholar] [CrossRef] [Scilit]
- Sigurgeirsson, B.; Steingrímsson, Ó. Risk factors associated with onychomycosis. J. Eur. Acad. Dermatol. Venereol. 2004, 18, 48–51. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gupta, A.K.; Taborda, P.; Taborda, V.; Gilmour, J.; Rachlis, A.; Salit, I.; Gupta, M.A.; MacDonald, P.; Cooper, E.A.; Summerbell, R.C. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int. J. Dermatol. 2000, 39, 746–753. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gupta, A.K.; Daigle, D.; Foley, K.A. The prevalence of culture-confirmed toenail onychomycosis in at-risk patient populations. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 1039–1044. [Google Scholar] [CrossRef] [Scilit]
- Jing, W.; Ismail, R. Mucocutaneous manifestations of HIV infection: A retrospective analysis of 145 cases in a Chinese population in Malaysia. Int. J. Dermatol. 1999, 38, 457–463. [Google Scholar] [CrossRef] [Scilit]
- Akkus, G.; Evran, M.; Gungor, D.; Karakas, M.; Sert, M.; Tetiker, T. Tinea pedis and onychomycosis frequency in diabetes mellitus patients and diabetic foot ulcers. A cross sectional - observational study. Pak. J. Med. Sci. 2016, 32, 891–895. [Google Scholar] [CrossRef] [Scilit]
- Vlahovic, T.C.; Sebag, J.A. Onychomycosis in Diabetics. In Onychomycosis: An Illustrated Guide to Diagnosis and Treatment; Tosti, A., Vlahovic, T.C., Arenas, R., Eds.; Springer International Publishing: Cham, Switzerland, 2017; pp. 169–174. [Google Scholar]
- Avner, S.; Nir, N.; Henri, T. Fifth toenail clinical response to systemic antifungal therapy is not a marker of successful therapy for other toenails with onychomycosis. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 1194–1196. [Google Scholar] [CrossRef] [Scilit]
- Araiza-Santibáñez, J.; Tirado-Sánchez, A.; González-Rodríguez, A.L.; Vázquez-Escorcia, L.; Ponce-Olivera, R.M.; Bonifaz, A. Onychomycosis in the elderly. A 2-year retrospective study of 138 cases. Rev. Med. Hosp. Gen. 2016, 79, 5–10. [Google Scholar] [CrossRef] [Scilit]
- Bang, C.H.; Yoon, J.W.; Lee, H.J.; Lee, J.Y.; Park, Y.M.; Lee, S.J.; Lee, J.H. Evaluation of relationships between onychomycosis and vascular diseases using sequential pattern mining. Sci. Rep. 2018, 8, 17840. [Google Scholar] [CrossRef] [Scilit]
- Lipner, S.R.; Scher, R.K. Onychomycosis: Clinical overview and diagnosis. J. Am. Acad. Dermatol. 2019, 80, 835–851. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kayarkatte, M.N.; Singal, A.; Pandhi, D. Impact of Onychomycosis on the Quality of Life: Dermatology Life Quality Index-Based Cross-Sectional Study. Skin Appendage Disord. 2020, 6, 115–119. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gupta, A.K.; Mays, R.R. The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature. Skin Appendage Disord. 2018, 4, 208–216. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lipner, S.R.; Scher, R.K. Onychomycosis: Treatment and prevention of recurrence. J. Am. Acad. Dermatol. 2019, 80, 853–867. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Roberts, D.T.; Taylor, W.D.; Boyle, J. Guidelines for treatment of onychomycosis. Br. J. Dermatol. 2003, 148, 402–410. [Google Scholar] [CrossRef] [Scilit]
- Gupta, A.K.; Paquet, M. Management of Onychomycosis in Canada in 2014. J. Cutan. Med. Surg. 2015, 19, 260–273. [Google Scholar] [CrossRef] [Scilit]
- Austin John Maddy, A.T. Systemic Treatment of Onychomycosis. In Onychomycosis: Diagnosis and Effective Management; Rigopoulos, D., Richert, B., Eds.; John Wiley & Sons Ltd: Hoboken, NJ, USA, 2018; pp. 118–122. [Google Scholar]
- Scher, R.K. Onychomycosis: A significant medical disorder. J. Am. Acad. Dermatol. 1996, 35, S2–S5. [Google Scholar] [CrossRef] [Scilit]
- Olafsson, J.H.; Sigurgeirsson, B.; Baran, R. Combination therapy for onychomycosis. Br. J. Dermatol. 2003, 149, 15–18. [Google Scholar] [CrossRef] [Scilit]
- Shemer, A.; Gupta, A.K.; Babaev, M.; Barzilai, A.; Farhi, R.; Daniel Iii, C.R. A Retrospective Study Comparing K101 Nail Solution as a Monotherapy and in Combination with Oral Terbinafine or Itraconazole for the Treatment of Toenail Onychomycosis. Skin Appendage Disord. 2018, 4, 166–170. [Google Scholar] [CrossRef] [Scilit]
- Gupta, A.; Joseph, W. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J. Am. Podiatr. Med. Assoc. 2000, 90, 495–501. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bunyaratavej, S.; Leeyaphan, C.; Rujitharanawong, C.; Surawan, T.M.; Muanprasat, C.; Matthapan, L. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis. J. Dermatol. Treat. 2016, 27, 359–363. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Flores, F.C.; Rosso, R.S.; Cruz, L.; Beck, R.C.R.; Silva, C.B. An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment. Eur. J. Pharm. Sci. 2017, 100, 56–63. [Google Scholar] [CrossRef] [Scilit]
- Bseiso, E.A.; Nasr, M.; Sammour, O.A.; Abd El Gawad, N.A. Novel nail penetration enhancer containing vesicles “nPEVs” for treatment of onychomycosis. Drug Deliv. 2016, 23, 2813–2819. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Angelo, T.; Borgheti-Cardoso, L.N.; Gelfuso, G.M.; Taveira, S.F.; Gratieri, T. Chemical and physical strategies in onychomycosis topical treatment: A review. Med. mycol. 2017, 55, 461–475. [Google Scholar] [CrossRef] [Scilit]
- Khattab, A.; Shalaby, S. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis. AAPS PharmSci. Tech. 2018, 19, 1048–1060. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lee, B.C.; Pangeni, R.; Na, J.; Koo, K.-T.; Park, J.W. Preparation and in vivo evaluation of a highly skin- and nail-permeable efinaconazole topical formulation for enhanced treatment of onychomycosis. Drug Deliv. 2019, 26, 1167–1177. [Google Scholar] [CrossRef] [Scilit]
- Murdan, S. Enhancing the nail permeability of topically applied drugs. Expert Opin. Drug Deliv. 2008, 5, 1267–1282. [Google Scholar] [CrossRef] [Scilit]
- Walters, K.A.; Abdalghafor, H.M.; Lane, M.E. The human nail – Barrier characterisation and permeation enhancement. Int. J. Pharm. 2012, 435, 10–21. [Google Scholar] [CrossRef] [Scilit]
- Elsayed, M.M.A. Development of topical therapeutics for management of onychomycosis and other nail disorders: A pharmaceutical perspective. J. Control. Release 2015, 199, 132–144. [Google Scholar] [CrossRef] [Scilit]
- Murdan, S. Drug delivery to the nail following topical application. Int. J. Pharm. 2002, 236, 1–26. [Google Scholar] [CrossRef] [Scilit]
- WALTERS, K.A.; FLYNN, G.L. Permeability characteristics of the human nail plate. Int J. Cosmet. Sci. 1983, 5, 231–246. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gunt, H.B.; Kasting, G.B. Effect of hydration on the permeation of ketoconazole through human nail plate in vitro. Eur. J. Pharm. Sci. 2007, 32, 254–260. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Benzeval, I.; Bowen, C.R.; Guy, R.H.; Delgado-Charro, M.B. Effects of Iontophoresis, Hydration, and Permeation Enhancers on Human Nail Plate: Infrared and Impedance Spectroscopy Assessment. Pharm. Res. 2013, 30, 1652–1662. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tabara, K.; Szewczyk, A.E.; Bienias, W.; Wojciechowska, A.; Pastuszka, M.; Oszukowska, M.; Kaszuba, A. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis. Adv. Dermatol. Allergol. 2015, 1, 40–45. [Google Scholar] [CrossRef] [Scilit]
- Murdan, S. Focal drug delivery to the nail. In Focal Controlled Drug Delivery; Springer: Berlin/Heidelberg, Germany, 2014; pp. 561–584. [Google Scholar]
- ICH Q8 (R2) (2009) Pharmaceutical Development. Available online: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf (accessed on 30 August 2017).
- ICH Q9 (2005) Quality Risk Management. Available online: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf (accessed on 30 August 2017).
- ICH Q10 (2008) Pharmaceutical Quality System. Available online: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf (accessed on 30 August 2017).
- Schlindwein, W.S.; Gibson, M. Pharmaceutical Quality by Design: A Practical Approach; John Wiley & Sons: Hoboken, NJ, USA, 2018. [Google Scholar]
- Srivastava, S.; Verma, U.; Kumar, R.; Bhatt, N. Preparation and Evaluation of Econazole Nitrate Containing Film-Forming Gel. Eur. J. Mol. Clin. Med. 2021, 8, 2881–2895. [Google Scholar]
- Aggarwal, R.; Targhotra, M.; Sahoo, P.; Chauhan, M.K. Onychomycosis: Novel strategies for treatment. J. Drug Deliv. Sci. Technol. 2020, 57, 101774. [Google Scholar] [CrossRef] [Scilit]
- Sharma, R.; Pathak, K. Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation. Pharm. Dev. Technol. 2011, 16, 367–376. [Google Scholar] [CrossRef] [Scilit]
- Patel, M.M.; Vora, Z.M. Formulation development and optimization of transungual drug delivery system of terbinafine hydrochloride for the treatment of onychomycosis. Drug Deliv. Transl. Res. 2016, 6, 263–275. [Google Scholar] [CrossRef] [Scilit]
- Alqahtani, A.; Raut, B.; Khan, S.; Mohamed, J.M.M.; Fatease, A.A.; Alqahtani, T.; Alamri, A.; Ahmad, F.; Krishnaraju, V. The Unique Carboxymethyl Fenugreek Gum Gel Loaded Itraconazole Self-Emulsifying Nanovesicles for Topical Onychomycosis Treatment. Polymers 2022, 14, 325. [Google Scholar] [CrossRef] [Scilit]
- Shah, V.H.; Jobanputra, A. Enhanced Ungual Permeation of Terbinafine HCl Delivered Through Liposome-Loaded Nail Lacquer Formulation Optimized by QbD Approach. AAPS PharmSci. Tech. 2018, 19, 213–224. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kushwaha, A.S.; Repka, M.A.; Narasimha Murthy, S. A Novel Apremilast Nail Lacquer Formulation for the Treatment of Nail Psoriasis. AAPS PharmSci. Tech. 2017, 18, 2949–2956. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Murthy, S.N.; Vaka, S.R.K.; Sammeta, S.M.; Nair, A.B. TranScreen-N™: Method for rapid screening of trans-ungual drug delivery enhancers. J. Pharm. Sci. 2009, 98, 4264–4271. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Aggarwal, R.; Targhotra, M.; Sahoo, P.K.; Chauhan, M.K. Efinaconazole nail lacquer for the transungual drug delivery: Formulation, optimization, characterization and in vitro evaluation. J. Drug Deliv. Sci. Technol. 2020, 60, 101998. [Google Scholar] [CrossRef] [Scilit]
- Rahman, A.; Aqil, M.; Ahad, A.; Imam, S.S.; Qadir, A.; Ali, A. Application of central composite design for the optimization of itraconazole loaded nail lacquer formulation. 3 Biotech 2021, 11, 1–16. [Google Scholar] [CrossRef] [Scilit]
- Joshi, M.; Sharma, V.; Pathak, K. Matrix based system of isotretinoin as nail lacquer to enhance transungal delivery across human nail plate. Int. J. Pharm. 2015, 478, 268–277. [Google Scholar] [CrossRef] [Scilit]
- Brown, M.B.; Khengar, R.H.; Turner, R.B.; Forbes, B.; Traynor, M.J.; Evans, C.R.G.; Jones, S.A. Overcoming the nail barrier: A systematic investigation of ungual chemical penetration enhancement. Int. J. Pharm. 2009, 370, 61–67. [Google Scholar] [CrossRef] [Scilit]
- Krawczyk-Santos, A.P.; da Rocha, P.B.R.; Kloppel, L.L.; Souza, B.d.S.; Anjos, J.L.V.; Alonso, A.; de Faria, D.L.A.; Gil, O.M.; Gratieri, T.; Marreto, R.N.; et al. Enhanced nail delivery of voriconazole-loaded nanomicelles by thioglycolic acid pretreatment: A study of protein dynamics and disulfide bond rupture. Int. J. Pharm. 2021, 602, 120597. [Google Scholar] [CrossRef] [Scilit]
- Shivakumar, H.; Vaka, S.R.K.; Madhav, N.S.; Chandra, H.; Murthy, S.N. Bilayered nail lacquer of terbinafine hydrochloride for treatment of onychomycosis. J. Pharm. Sci. 2010, 99, 4267–4276. [Google Scholar] [CrossRef] [Scilit]
- Saner, M.V.; Kulkarni, A.D.; Pardeshi, C.V. Insights into drug delivery across the nail plate barrier. J. Drug Target. 2014, 22, 769–789. [Google Scholar] [CrossRef] [Scilit]




| Formulation # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ECN (%w/w) | 1 | 3 | 5 | 7 | 10 | 1 | 3 | 5 | 7 | 10 | 1 | 3 | 5 | 7 | 10 |
| Ethanol/Water | 80:20 | 70:30 | |||||||||||||
| Polymer Content (%w/w) | 5 | 7.5 | |||||||||||||
| 2-mercaptoethanol (%w/w) | 5 | ||||||||||||||
| PEG 400 (%w/w) | 10 | ||||||||||||||
| Factors (Independent Variables) | Responses (Dependent Variables) | Fixed Parameters | ||
|---|---|---|---|---|
| X1 | X2 | X3 | ||
| Polymer | Solvent | Plasticizer | ||
| E-RL100 | IPA:Acetone | Glycerol | Y1 Drying Time | Batch Volume—10 mL |
| E-RLPO | IPA:Butanol | PEG 400 | Y2 Water Resistance | Polymer Content—30% w/w |
| E-RS100 | Triacetin | Y3 Adhesion | Plasticizer Concentration—30% w/w | |
| E-RSPO | Drug Solubilizer (Tween 80)—0.25% w/w | |||
| IPA:Butanol—5:1 | ||||
| IPA:Acetone—3:2 | ||||
| Factors (Independent Variables) | Responses (Dependent Variables) | Fixed Parameters | ||
|---|---|---|---|---|
| X1 (%w/w) | X2 (%w/w) | |||
| Levels | E-RSPO Concentration | Triacetin Concentration | ||
| −1 | 10 | 10 | Y1 D50 Drying Time | Batch Volume—10 mL |
| 0 | 20 | 20 | Y2 Water Resistance | Drug Solubilizer Tween 80—0.25% w/w |
| +1 | 30 | 30 | Y3 Adhesion | IPA:Acetone—3:2 |
| QTPP Element | Target | CQA | Justification |
|---|---|---|---|
| Dosage form | Nail lacquer | Promising transungual dosage form as demonstrated in the literature | |
| Route of administration | Topical | To prevent adverse drug effects and delivery at the site of infection | |
| Dosage strength | Maximal drug-loading | To achieve drug load > MIC: 0.2 µg/mL | |
| Drying time | <2 min | ✓ | To prevent removal while drying and to increase patient compliance |
| Water resistance | At least 24 h | ✓ | To prevent washout with daily handwashing |
| Adhesion | Maximize | ✓ | To prevent removal of drug film with daily activities |
| Factors (Independent Variables) | Responses (Dependent Variables) * | |||
|---|---|---|---|---|
| X1 | X2 | Y1 (s) | Y2 (%) | Y3 (%) |
| Polymer | Plasticizer | Drying Time | Water Resistance | Adhesion |
| RLPO | Triacetin | 165 | 33.8 | 100 |
| RSPO | Glycerol | 45 | 32.6 | 0 |
| RLPO | Glycerol | 45 | 32.4 | 77.78 |
| RS100 | PEG 400 | 105 | 30.1 | 0 |
| RSPO | PEG 400 | 90 | 29.6 | 88.89 |
| RSPO | Triacetin | 105 | 28.9 | 100 |
| RL100 | PEG 400 | 150 | 34.4 | 100 |
| RL100 | Glycerol | 75 | 33.8 | 11.11 |
| RS100 | Glycerol | 60 | 31.7 | 100 |
| RL100 | Triacetin | 165 | 33.7 | 100 |
| RS100 | Triacetin | 135 | 33.2 | 100 |
| RLPO | PEG 400 | 120 | 31.9 | 100 |
| Factors (Independent Variables) | Responses (Dependent Variables) * | |||
|---|---|---|---|---|
| X1 (% w/w) | X1 (% w/w) | Y1 (s) | Y2 (%) | Y3 (%) |
| RSPO Concentration | Triacetin Concentration | D50 Drying Time | Water Resistance | Adhesion |
| 10 | 20 | 39 | 28 | 100 |
| 10 | 30 | 45 | 38 | 100 |
| 20 | 20 | 87.33 | 16 | 100 |
| 30 | 30 | 168 | 30 | 100 |
| 20 | 30 | 84.33 | 28 | 100 |
| 10 | 10 | 49 | 18 | 100 |
| 20 | 10 | 89.5 | 12 | 100 |
| 30 | 20 | 207 | 25 | 100 |
| 30 | 10 | 120.67 | 27 | 100 |
| Excipient | Concentration (% w/w) | |
|---|---|---|
| LQ10 | LQ20 | |
| E-RSPO | 10 | 20 |
| Triacetin | 10 | 10 |
| ECN | 2 | 2.25 |
| Excipient | Concentration (% w/w) | |
|---|---|---|
| Test Lacquer | Control Lacquer | |
| E-RSPO | 10 | 10 |
| Triacetin | 10 | 10 |
| ECN | 2 | 2 |
| Kolliphor CS 20 | 5 | - |
| Tween 80 | 0.25 | 0.25 |
| Solvent | QS to 100 | QS to 100 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Puri, V.; Savla, R.; Chen, K.; Robinson, K.; Virani, A.; Michniak-Kohn, B. Antifungal Nail Lacquer for Enhanced Transungual Delivery of Econazole Nitrate. Pharmaceutics 2022, 14, 2204. https://doi.org/10.3390/pharmaceutics14102204
Puri V, Savla R, Chen K, Robinson K, Virani A, Michniak-Kohn B. Antifungal Nail Lacquer for Enhanced Transungual Delivery of Econazole Nitrate. Pharmaceutics. 2022; 14(10):2204. https://doi.org/10.3390/pharmaceutics14102204
Chicago/Turabian StylePuri, Vinam, Riya Savla, Kevin Chen, Keyaara Robinson, Amitkumar Virani, and Bozena Michniak-Kohn. 2022. "Antifungal Nail Lacquer for Enhanced Transungual Delivery of Econazole Nitrate" Pharmaceutics 14, no. 10: 2204. https://doi.org/10.3390/pharmaceutics14102204
APA StylePuri, V., Savla, R., Chen, K., Robinson, K., Virani, A., & Michniak-Kohn, B. (2022). Antifungal Nail Lacquer for Enhanced Transungual Delivery of Econazole Nitrate. Pharmaceutics, 14(10), 2204. https://doi.org/10.3390/pharmaceutics14102204

